International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 5122 | 2014 |
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2560 | 2016 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ... New England Journal of Medicine 359 (9), 906-917, 2008 | 2474 | 2008 |
Daratumumab, bortezomib, and dexamethasone for multiple myeloma A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... New England Journal of Medicine 375 (8), 754-766, 2016 | 1684 | 2016 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1594 | 2015 |
Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1528 | 2015 |
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hajek, ... Leukemia 23 (2), 215-224, 2009 | 1041 | 2009 |
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ... New England Journal of Medicine 378 (6), 518-528, 2018 | 981 | 2018 |
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ... The Lancet 387 (10027), 1551-1560, 2016 | 980 | 2016 |
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 958 | 2012 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 953 | 2016 |
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up P Moreau, J San Miguel, P Sonneveld, MV Mateos, E Zamagni, ... Annals of oncology 28, iv52-iv61, 2017 | 859 | 2017 |
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report A Palumbo, S Bringhen, MV Mateos, A Larocca, T Facon, SK Kumar, ... Blood, The Journal of the American Society of Hematology 125 (13), 2068-2074, 2015 | 782 | 2015 |
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 752 | 2022 |
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up MA Dimopoulos, P Moreau, E Terpos, MV Mateos, S Zweegman, G Cook, ... Hemasphere 5 (2), e528, 2021 | 642 | 2021 |
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma MV Mateos, MT Hernández, P Giraldo, J De la Rubia, F De Arriba, ... New England Journal of Medicine 369 (5), 438-447, 2013 | 637 | 2013 |
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis … E Pérez-Persona, MB Vidriales, G Mateo, R García-Sanz, MV Mateos, ... Blood, The Journal of the American Society of Hematology 110 (7), 2586-2592, 2007 | 637 | 2007 |
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ... Leukemia 31 (10), 2094-2103, 2017 | 604 | 2017 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 587 | 2010 |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in … MV Mateos, PG Richardson, R Schlag, NK Khuageva, MA Dimopoulos, ... Journal of Clinical Oncology 28 (13), 2259-2266, 2010 | 574 | 2010 |